Abstract Number: PB1128
Meeting: ISTH 2020 Congress
Background: Direct oral anticoagulants (AOD) are prescribed for both atrial fibrillation (AF) and venous thromboembolic disease (VTE). In addition, like any anticoagulant treatment, their use may be associated with the occurrence of haemorrhagic complications. To our knowledge, no study compared hemorrhagic events between these two indications.
Aims: The aim of our study is to compare these two populations in terms of hemorrhagic incidence and clinical-biological characteristics.
Methods: We performed a retrospective and monocentric study from RATED database (NCT02706080) in our emergency department. Major patients under DOACs, for AF or VTE, were included. Patients treated for dual VTE and AF indication were excluded
Results: Of 525 patients included, 100 patients (19%) were on Dabigatran, 282 (54%) on Rivaroxaban and 143 (27%) on Apixaban with 149 patients (28.4%) treated with VTE and 376 (71.6%) with AF . Of the 95 patients who had hemorrhage, 27 patients (28.4%) were treated for VTE and 68 (71.6%) for AF, or 18.4% hemorrhages in the VTE group versus 18.3% in the AF group. Patients in the AF group were older (77.4 ± 11.0 vs 62.8 ± 19.6, p < 0.001), had more arterial hypertension (51.9% vs 33.6%, p < 0.001), more stroke (21.1% vs 8.7%, p < 0.001), more myocardial infarction (21.8% vs 13.1%, p = 0.029), more associated treatments (3.7 versus 3, p < 0.001), and higher hemorrhagic risk scores. Paradoxically, when analyzing subgroups "AF with haemorrhage" versus "VTE with bleeding", apart from the persistent age difference (78.6 ± 10.2 versus 60.6 ± 21.1, p < 0.001), the medical history became comparable in the two groups.
Conclusions: Our study showed that during the occurrence of a haemorrhagic event differences between AF and VTE patients faded, suggesting that patients with bleeding do not differ, regardless of the therapeutic indication.
To cite this abstract in AMA style:Moustafa F, Fleuchot T, Teissandier D, Schmidt J. Direct Oral Anticoagulants Bleeding Events in Patients with Atrial Fibrillation Vs Venous Thromboembolism Admitted to an Emergency Department: Real-Life Study [abstract]. Res Pract Thromb Haemost. 2020; 4 (Suppl 1). https://abstracts.isth.org/abstract/direct-oral-anticoagulants-bleeding-events-in-patients-with-atrial-fibrillation-vs-venous-thromboembolism-admitted-to-an-emergency-department-real-life-study/. Accessed January 28, 2022.
« Back to ISTH 2020 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/direct-oral-anticoagulants-bleeding-events-in-patients-with-atrial-fibrillation-vs-venous-thromboembolism-admitted-to-an-emergency-department-real-life-study/